Cargando…
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes
INTRODUCTION: Ki-67 labeling index assessed by immunohistochemical assays has been shown useful in assessing the risk of recurrence for estrogen receptor (ER)-positive HER2-negative breast cancers (BC) and distinguishing Luminal A-like from Luminal B-like tumors. We aimed to assess the performance o...
Autores principales: | Viale, Giuseppe, Hanlon Newell, Amy E., Walker, Espen, Harlow, Greg, Bai, Isaac, Russo, Leila, Dell’Orto, Patrizia, Maisonneuve, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797656/ https://www.ncbi.nlm.nih.gov/pubmed/31422497 http://dx.doi.org/10.1007/s10549-019-05402-w |
Ejemplares similares
-
MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers
por: Sadeghian, Dorsay, et al.
Publicado: (2022) -
Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information
por: Inic, Zorka, et al.
Publicado: (2014) -
Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up
por: Bustreo, Sara, et al.
Publicado: (2016) -
Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value
por: Ciruelos, E, et al.
Publicado: (2011) -
Can Histological Grade and Mitotic Index Replace Ki67 to Determine Luminal Breast Cancer Subtypes?
por: Oddó, David, et al.
Publicado: (2018)